Sold as Forteo, Bonsity, Teriparatide. Every FDA application for this active ingredient: 3 branded and 4 generic.
As of Nov 15, 2026, FDA lists 7 applications for Teriparatide (sold as Forteo, Bonsity, Teriparatide), first approved Nov 26, 2002, with 3 new uses approved and 0 published complete response letters.
| Teriparatide | Part D | $315M | +48% | 23,973 |
| Forteo | Part D | $294M | +11% | 13,224 |
| Bonsity | Part D | $4.0M | New | 638 |
| A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing RegimensPostmenopausal Women With Osteoporosis · Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Recruiting | May 12, 2026 |
| A Study of B-3E07 and Forsteo® in Healthy Adult Female ParticipantsHealthy Volunteers · Syneos Health | Phase 1 | Recruiting | Mar 27, 2026 |
| Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal OsteoporosisCircadian Rhythm Disorders, Osteoporosis · Peking University Third Hospital | Not applicable | Not yet recruiting | Apr 30, 2025 |
| To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of FracturePostmenopausal Women With Osteoporosis · Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Mar 27, 2025 |
| Relationship Between Thoracic Hyperkyphosis and Fall Risk in Women with Fragility Vertebral FracturesOsteoporosis, Hyperkyphosis · University of Palermo | — | Active, not recruiting | Feb 24, 2025 |
| Combined Anabolic TherapyOsteoporosis, Postmenopausal, Osteoporosis · Massachusetts General Hospital | Phase 4 | Recruiting | Aug 16, 2024 |
| PROactive HEALing in High-Risk Pelvic and Non-hip Lower Extremity Fragility Fractures (PRO HEAL Pilot)Lower Extremity Fractures, Pelvis · University of Calgary | Phase 1 / Phase 2 | Not yet recruiting | Mar 12, 2024 |
| Precision Medicine Approach for Osteoporosis - Follow Up StudyOsteoporosis · Paul F Netzel | Phase 4 | Enrolling by invitation | Feb 20, 2024 |
| Nov 26, 2002 | ForteoNDA 21318 · New dosage form | Lilly | 25 | Marketed |
| Oct 4, 2019 | BonsityNDA 211939 · New formulation or manufacturer | Alvogen | 3 | Marketed |
| Nov 16, 2023 | TeriparatideANDA 208569 | Teva Pharms USA | 1 | Marketed |
| Nov 16, 2023 | TeriparatideANDA 211097 | Apotex | 1 | Marketed |
| Jun 4, 2024 | TeriparatideNDA 218771 · New formulation or manufacturer | Almaject | 2 | Marketed |
| Dec 12, 2025 | TeriparatideANDA 213641 | Amphastar Pharms Inc | 0 | Marketed |
| Oct 23, 2026 | TeriparatideANDA 214412 | Dr Reddys | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Lilly
Apotex